Researchers analyzed prospectively collected data from the UK Medical Cannabis Registry for 101 biological females with a primary diagnosis of endometriosis who had been enrolled at least two years before the June 1, 2025 data extraction.

Patients were followed at baseline and again at 1, 3, 6, 12, 18, and 24 months, tracking BPI Severity, BPI Interference, SF-MPQ-2 Total, Pain VAS, EQ-5D-5L quality of life, GAD-7 anxiety, sleep quality (SQS), and prescribed oral morphine equivalents.

BPI Severity, BPI Interference, SF-MPQ-2 Total, Pain VAS, and EQ-5D-5L Index all showed statistically significant improvement from baseline at every single follow-up point, from 1 month all the way through 24 months (p<0.001).

That consistency across seven separate follow-up windows and multiple validated pain and quality-of-life instruments is one of the more notable features of this dataset for a chronic, often treatment-resistant condition.

GAD-7 anxiety scores and the Sleep Quality Scale also improved significantly from baseline at every follow-up point (p<0.001), suggesting the reported benefit was not limited to pain measures alone.

Endometriosis-related pain, poor sleep, and anxiety commonly reinforce one another, so parallel improvement across all three domains is a coherent pattern, though it does not by itself prove which factor is driving which.

Mean prescribed oral morphine equivalents fell from 19.9±17.2 mg/day at baseline to 14.8±15.9 mg/day at 24 months, a real-world signal that some patients may have been able to reduce opioid dosing while enrolled in cannabis-based treatment.

This is a prescribing trend within an observational cohort, not a controlled opioid-sparing trial, so it should be read as a hypothesis worth testing rather than a demonstrated opioid-reduction effect of CBMPs.

Eighteen participants, 17.8% of the cohort, reported a combined 165 adverse events, of which 84 (50.9%) were classified as mild. The most frequently reported were fatigue (n=16, 15.8%), lethargy (n=15, 14.9%), and headache (n=13, 12.9%).

That a meaningful minority of patients experienced adverse effects, even when most were mild, is worth naming plainly rather than glossing over in favor of the positive outcome data.

This was a single-arm, before-and-after observational analysis with no placebo or control group, no blinding, and outcomes measured entirely through patient-reported instruments.

The UK Medical Cannabis Registry operates through Curaleaf Clinic, and several authors are affiliated with that clinic, a relevant disclosure given that the same organization that enrolls, treats, and follows patients also has a commercial interest in favorable outcomes. The authors themselves state that randomised controlled trials are required to establish efficacy and safety.

This registry analysis adds to a small but growing body of real-world CBMP data in endometriosis, joining earlier, shorter cohort reports that also found improvement in pain and quality-of-life measures over shorter observation windows. What this analysis adds is duration, following the same patients out to 24 months rather than weeks, and a broader outcome set that includes anxiety, sleep, and opioid prescribing alongside pain.

The next meaningful step, as the study authors themselves note, is a randomized controlled trial with a genuine placebo or active comparator arm, which is the only design capable of separating a true pharmacological effect from the substantial nonspecific benefits that come from structured clinical engagement, expectation, and the natural course of a fluctuating chronic pain condition.

I have been practicing family medicine and cannabis medicine for more than 20 years, and this is the kind of dataset I want to see more of for endometriosis: a real cohort followed carefully over two full years, with validated pain, quality of life, anxiety, and sleep measures all moving in the same encouraging direction, plus an opioid dosing trend that matters in daily practice. That consistency across seven follow-up points is not nothing, and for a condition where many patients feel dismissed or run out of good options, this data is worth taking seriously.

At the same time, I have to be honest about what this study is and is not. It is a single-arm, before-and-after registry analysis with no placebo group, no blinding, and patient-reported outcomes from people who chose to start and stayed on cannabis treatment. That design cannot separate a genuine drug effect from placebo response, regression to the mean, or the simple benefit of feeling cared for by a structured clinic program. The registry runs through a commercial cannabis clinic, which is a conflict of interest worth stating plainly rather than glossing over. I read this as a promising, real-world signal that supports doing the randomized trial the authors themselves call for, not as proof that cannabis treats endometriosis. If a patient of mine with endometriosis asks about this study, I would frame it exactly that way: encouraging, but not yet conclusive.

A Four-Step Reading Frame